Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1980
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
J01DD01
|
| gptkbp:bioavailability |
not orally available
|
| gptkbp:brand |
gptkb:Claforan
|
| gptkbp:CASNumber |
63527-52-6
|
| gptkbp:contraindication |
hypersensitivity to cephalosporins
|
| gptkbp:drugClass |
gptkb:cephalosporin
|
| gptkbp:eliminationHalfLife |
1 hour
|
| gptkbp:excretion |
gptkb:kidney
|
| gptkbp:hasInChIKey |
QZRKYBIIGXBKQF-GHXIOONMSA-N
|
| gptkbp:hasMolecularFormula |
C16H17N5O7S2
|
| gptkbp:hasSMILES |
CC1=C(N2C(S1(=O)=O)C(=O)NC2C(=O)NC(C3=CSC=N3)C(=O)O)COC(=O)N
|
| gptkbp:hasUNII |
M8Y5M7SF2M
|
| gptkbp:indication |
meningitis
septicemia urinary tract infections gonorrhea bacterial infections respiratory tract infections intra-abdominal infections skin and soft tissue infections bone and joint infections gynecological infections prophylaxis in surgery |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits bacterial cell wall synthesis
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
455.463
|
| gptkbp:name |
gptkb:Cefotaxime
|
| gptkbp:pregnancyCategory |
B
|
| gptkbp:proteinBinding |
30-50%
|
| gptkbp:PubChem_CID |
gptkb:DB00034
3494 5479530 D00254 |
| gptkbp:routeOfAdministration |
intramuscular
intravenous |
| gptkbp:sideEffect |
nausea
vomiting diarrhea rash elevated liver enzymes eosinophilia |
| gptkbp:synonym |
cefotaxime sodium
cefotaximum |
| gptkbp:target |
penicillin-binding proteins
|
| gptkbp:bfsParent |
gptkb:Roferon-A
gptkb:Interferon_alpha-2A |
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
DB00034
|